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Abstract
Background: Non-organ-specific autoantibodies are found in a considerable number of anti-HCV positive
patients. Previous studies investigated the clinical relevance of these antibodies in patients treated with interferon
monotherapy, but not combination therapies.
Methods: Anti-nuclear, anti-smooth muscle, anti-mitochondrial, anti-neutrophil-cytoplasmatic and anti-liver/
kidney microsomal antibodies were determined in 78 consecutive anti-HCV positive patients by indirect
immunofluorescence. The presence of these antibodies was related to demographic variables and to the outcome
of antiviral combination therapy with interferon-α and ribavirin in 65 patients.
Results: In our study, positivity for autoantibodies was associated with higher alanine aminotransferase levels and
higher mean values for HCV-RNA (p < 0.01). Furthermore, negativity for non-organ-specific autoantibodies was
associated with a favourable treatment outcome of combination therapy with at least one negative RT-PCR for
HCV-RNA during treatment (OR 4.65, 95% CI 1.31 to 16.48, p = 0.02). ANA and SMA staining patterns and titers
were not correlated to treatment response. With multiple logistic regression analysis, positivity for
autoantibodies and HCV genotype were independently associated with outcome of antiviral combination therapy
(p = 0.02).
Conclusions: The absence of non-organ-specific autoantibodies might indicate a significantly higher chance for
viral clearance in response to combination therapy for chronic hepatitis C infection. Therefore, despite of an
overall higher treatment response, the addition of the immunomodulatory drug ribavirin could accentuate
immunological differences that affect treatment outcome and might have been less obvious in earlier studies
analysing interferon monotherapy.
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Background
Various immunological phenomena have been described
in patients being exposed to the hepatitis C virus (HCV)
[1]. Organ-specific and non-organ-specific autoantibodies
are found in a considerable number of patients with acute
and chronic hepatitis C [2]. Especially the high percentage
of non-organ-specific autoantibodies (NOSA) in chronic
infection has led to further investigation of the potential
biological relevance of these findings. In recent studies the
prevalence of different NOSA, including anti-nuclear anti-
bodies (ANA), anti-smooth muscle antibodies (SMA),
anti-mitochondrial antibodies (AMA), anti-neutophil-
cytoplasmatic antibodies (ANCA), and anti-liver/kidney
micosomal antibodies (LKM) were investigated before,
during and after monotherapy with interferon-α for
chronic hepatitis C [3,4]. However, there is little informa-
tion on NOSA prevalence in patients treated with current
standard therapy, i.e. the combination of interferon-α and
ribavirin. This should be investigated, as ribavirin has
been demonstrated to have distinct immunomodulatory
effects [5,6]. Furthermore, the former analyses of the
influence of NOSA on the clearance of the hepatitis C
virus upon monotherapy with interferon-α are controver-
sial, with a few studies showing a tendency to a poorer
treatment response in autoantibody-positive subjects
while other investigations could not demonstrate any dif-
ference in the efficacy of therapy [3,7,8]. However, there
are no studies so far that investigated the relevance of
NOSA with regards to the virological and biochemical
response in patients treated with interferon-α plus ribavi-
rin. This combination therapy now represents the treat-
ment of choice since it has been proven to be superior to
interferon monotherapy in large randomised trials [9].
The aim of the present study was to determine the preva-
lence of NOSA in patients positive for anti-HCV antibod-
ies and to systematically analyse the potential impact of
these antibodies on the efficacy of a combined antiviral
therapy with interferon-α and ribavirin in patients with
chronic hepatitis C infection.
Methods
Patients and diagnosis of hepatitis C
A total of 78 patients were enrolled in the study between
1999 and the end of 2000. All patients were found to be
anti-HCV positive in a second-generation enzyme-linked
immunosorbent assay (Abbot Ltd., USA). Patients with a
repeatable (> six months) positive viral RNA (> 600 viral
copies/ml, Cobas Amplicor, Roche, Switzerland, n = 65
individuals) were considered to have chronic hepatitis C
virus infection.
As the study included the measurement of autoantibod-
ies, all subjects were thoroughly screened for autoimmune
diseases during physical examination and history taking.
A panel of standard laboratory parameters, including
hematological, coagulation and serological parameters
was taken from all subjects. In all patients mean daily
alcohol intake was below 40 g. Serum assays for the hep-
atitis B virus surface antigen and human immunodefi-
ciency virus were negative (all assays from Abbott Ltd.,
USA). The laboratory values for α1-antitrypsin, transferrin
saturation and coeruloplasmin were within normal
ranges in all subjects.
Furthermore, all patients were evaluated according to the
revised scoring system for the diagnosis of autoimmune
hepatitis. Using this algorithm, none of the patients inves-
tigated in our study displayed a score of more than 10
points, excluding autoimmune hepatitis as the underlying
liver disease with a high sensitivity and specificity in our
patients [10].
Liver Histology
All subjects who were found positive for HCV-RNA under-
went percutaneous liver biopsy and histological parame-
ters were classified according to the score system of Batts
and Ludwig [11]. The necro-inflammatory activity in the
obtained specimen was graded from 0 (no activity) to 4
(severe activity) by a pathologist blinded to the study
design (J.L.).
Antiviral combination therapy
Table 1: Prevalence of non-organ specific autoantibodies in anti-HCV positive patients (n = 78).
Autoantibody (Titer ≥ 1:40 by IFL) n (%)
ANA 15 (19.2)
SMA 25 (32.0)
AMA 2 (2.6)
ANCA 4 (5.2)
LKM 0 (0)
Any autoantibody 36 (46.2)
ANA and/or SMA 33 (42.3)
All serum autoantibodies were determined by indirect immunofluorescence (IFL). A serum dilution of at least 1:40 was considered as a positive 
result. ANA, anti-nuclear antibodies; SMA, anti-smooth muscle anibodies; AMA, anti-mitochondrial antibodies, ANCA, anti-neutophil-cytoplasmatic 
antibodies; LKM, anti liver/kidney microsomal antibodiesBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/4
Page 3 of 8
(page number not for citation purposes)
Overall, 48 patients with chronic hepatitis C infection
were treated with 3 million units interferon-α 2a (20 sub-
jects) or 2b (28 subjects) three times a week and 1000 or
1200 mg ribavirin daily depending on body weight.
HCV-RNA was tested after 4, 12, 24 and 48 weeks during
therapy and 4, 12 and 24 weeks after completion of ther-
apy. Overall, there were 17 sustained responders (35.4%)
and 4 relapsers (8.3%), while 27 subjects showed no viro-
logical response (56.3%). In anticipation of a small
number of patients in our single-centre study, we initially
decided that any negative RT-PCR during treatment or
thereafter should be considered as a positive treatment
response for the purpose of this particular investigation.
After completion of patients' enrolment all analyses were
re-calculated with stratification of patients according to
the current standard criteria for treatment response [9].
The study protocol was approved by the local ethic com-
mittee in accordance to the Declaration of Helsinki.
Autoantibody determination
ANA, AMA, SMA, ANCA and LKM antibodies were
searched for by indirect immunofluorescence (IFL) on
Hep-2 cells, cryostat sections of rat liver, kidney, stomach,
and human granulocytes, respectively. The initial dilution
was 1:20 following standard protocols [12,13]. Positive
reactions were titrated by double dilution to the end
point. Serum reactivity at a dilution of at least 1:40 was
considered as a positive result for all autoantibodies in
this study. ANA and SMA staining patterns were identified
according to published protocols [12,13]. Antibody
assays were performed prior to and during antiviral
treatment.
Data collection and statistical analysis
Continuous variables were compared by using the
unpaired Student's t test with Welsh correction in case of
unequal variances. Univariate analysis of dichotomous
variables in contingency tables was performed with
Fisher's exact test. Multivariate analysis was done by logis-
tic regression analysis with treatment outcome as depend-
ent variable and presence of autoantibodies, HCV
genotype and HCV-RNA concentrations as covariates.
Univariate and regression analyses were performed with
STATA 7.0 software (College Station, TX,, USA), employ-
ing a package of commands (Genassoc) written by D.
Clayton and available from http://www-
gene.cimr.cam.ac.uk/.
Results
Demographic analysis
Table 1 summarises the autoantibody prevalence in our
study patients. Overall, 36 patients had at least one NOSA
(ANA, AMA, ANCA, or SMA) at a titer higher than 1:40 as
determined by IFL. SMA was the most frequent autoanti-
body (32.0%) followed by ANA in 19.2% of the subjects.
AMA and ANCA were detected in only a small number of
cases at low titers (n = 2 and n = 4, respectively) and no
anti-M2 antibodies were found in the AMA-positive sera.
Furthermore, in the two patients who were tested positive
for AMA, values for IgM and bilirubin were within the
normal range and the liver biopsies revealed no signs of
primary biliary cirrhosis. LKM antibodies were not detect-
able in our patients. For further analysis the patients were
divided in two groups, as shown in table 2. The first group
comprised the subjects without NOSA; the second group
represented autoantibody-positive patients.
Table 2 demonstrates that there were no differences
between the groups regarding age, HCV genotype distri-
bution, AST, albumin and IgG to cytomegaly virus, or
Ebstein-Barr virus. Of note, there were also no significant
differences between autoantibody-positive and autoanti-
body-negative subjects with regards to levels of total IgG,
IgM, and IgA. The necro-inflammatory activity upon his-
tological examination of the liver biopsies also did not
reveal a significant difference between the groups. In con-
trast, ALT values and the concentrations of HCV-RNA
were significantly higher in autoantibody-positive
patients compared to autoantibody-negative subjects (p =
0.006 and p = 0.007, respectively).
Association between NOSA and efficacy of antiviral 
therapy
Figures 1 and 2 illustrate the potential interactions
between NOSA and response to antiviral treatment. Over-
all, 78 patients with positive anti-HCV were included in
the study. In 65 subjects (83.3%) HCV-RNA was detecta-
ble for more than six months, indicating a chronic viral
infection. In 13 patients (16.7%) no viral replication was
found upon repeated testing by RT-PCR, suggesting spon-
taneous viral clearance. Figure 1 illustrates that in 3 of
these 13 patients at least one NOSA could be detected,
while no autoantibodies were found in the majority (n =
10) of these patients (OR 3.44, 95% CI 0.87 to 13.65, p =
0.07).
In 48 of 65 patients with measurable viral replication a
combination therapy with interferon-α and ribavirin
adjusted to body weight was initiated. Twenty-seven
patients had no detectable antibodies before or during
treatment, whereas in 21 cases at least one NOSA was
detected. HCV genotype distributions were similar
between groups. Overall, 21 of the 48 treated patients
showed a virological response to treatment with a repeat-
able negative RT-PCR during or after completion of the
therapy. Figure 2 depicts that 16 of these 21 patients
(76.2%) had no detectable autoantibodies during the
course of the study, whereas only 5 patients (23.8%) wereBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/4
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positive for any NOSA. This favourable treatment
response in autoantibody-negative individuals was signif-
icant in univariate analysis (OR 4.65, 95% CI 1.31 to
16.48, p = 0.019). We additionally calculated a regression
analysis to control for known predictive factors related to
the outcome of antiviral treatment. In this multivariate
analysis, positivity for autoantibodies (OR 7.4, CI 1.3 –
39.5, p = 0.02) and HCV genotype (OR 6.1, CI 1.0 – 36.2,
p = 0.048) were both independently associated with the
outcome of antiviral therapy.
Titers and staining patterns of ANA and SMA in relation to 
antiviral therapy
Table 3 displays the prevalence, titers and staining pat-
terns of ANA and SMA in patients with a response or non-
response to treatment with interferon-α and ribavirin. Of
these two autoantibodies, SMA were detectable at signifi-
cantly higher frequencies in non-responders compared to
patients with a sustained response to antiviral therapy
(OR 4.8, CI 1.4 – 20.2, p = 0.03). In contrast, the titers of
ANA and SMA did not differ between the groups. ANA
showed a speckled pattern in all cases, whereas only one
patient had SMA without a vessel wall staining pattern.
Discussion
The nucleoside analogue ribavirin has been demonstrated
to increase the efficacy of antiviral treatment for hepatitis
C when used in combination with interferon-α [9]. As the
role of the balance between Th1- and Th2-associated
cytokines has been shown to be of primary importance in
Overall results of 78 anti-HCV positive patients were screened for HCV-RNA. Figure 1
Overall, 78 anti-HCV positive patients were screened for HCV-RNA. IN 65 patients (83.3%) HCV-RNA was detected. In 13 
patients (16.7%) no HCV-RNA was found upon repeated testing, suggesting viral clearance in these patients. There is a trend 
towards a higher rate of viral clearance in patients without NOSA compared to patients with NOSA (p = 0.07, Fisher's exact 
test). NOSA, non-organ-specific autoantibodies.
78 patients positive 
for anti-HCV
65 patients positive 
for HCV-RNA (83.3%)
13 patients negative 
for HCV-RNA (16.7%)
33 patients positive 
for NOSA (50.8%)
32 patients negative 
for NOSA (49.2%)
3 patients positive 
for NOSA (23.1%)
10 patients negative 
for NOSA (76.9%)BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/4
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antiviral therapy [14], the superiority of the current stand-
ard treatment might be partly attributed to the immu-
nomodulatory properties of ribavirin [5,6,15]. The aim of
our study was to assess whether such properties of ribavi-
rin could unmask clinical differences with relation to the
presence of autoantibodies in patients with hepatitis C.
Therefore, we first determined the prevalence of NOSA in
a cohort of 78 anti-HCV positive patients. In our study, a
total of 46.2% of subjects had at least one NOSA, with
ANA and SMA showing the highest prevalence rates
(19.2% and 32.0%, respectively). The prevalence of
NOSA in our patients is comparable to previous studies
[2,16], which demonstrated these antibodies to be present
at similar frequencies. AMA and ANCA have been rarely
found in patients with hepatitis C [17,18], which was con-
firmed in our cohort of patients. In contrast to other inves-
tigations [16,19], LKM antibodies were not detected in
our patients, most likely due to the sample size and the
cut-off for positivity of immunofluorescence (reactivity at
serum dilution ≥ 1: 40) in our study. The analysis of ANA
and SMA subspecificities revealed that the vast majority of
these autoantibodies in our study subjects were ANA with
a speckled pattern and SMA with a vessel wall staining pat-
tern, which is in line with earlier findings [7,16,20]. In
65 patients with viral persistence for more than six months antiviral therapy was considered. Figure 2
65 patients with viral persistence for more than six months antiviral therapy was considered. Seventeen patients were 
excluded from antiviral therapy due to contraindications, i.e. repeatable normal ALT values, severe psychiatric disorders, or 
persistent drug abuse. Forty-eight patients were treated with interferon-α and ribavirin for at least six months. Overall, 21 
patients (48.3%) had at least one negative RT-PCR for HCV-RNA, while 27 patients (56.2%) did not show a virological 
response. Among the patients who responded to the therapy 76.2% had no detectable NOSA, while 23.8% were positive for 
NOSA. Absence of NOSA was statistically associated with a favourable treatment response (OR 4.65, 95% CI 1.31 to 16.48, 
Fisher's exact test) in univariate and multivariate analysis. ALT, alanine aminotranferase; NOSA, non-organ-specific autoanti-
bodies; RT-PCR, reverse transcriptase polymerase chain reaction; OR, odds ratio; CI, contraindications.
65 patients with 
positive HCV-RNA  
> 6 months evaluated 
for therapy
17 patients without 
therapy                         
(CI or normal ALT)
48 patients with 
IFN / ribavirin 
therapy
21 patients with 
response to 
therapy (43.8%)
27 patients without 
response to therapy 
(56.2%)
5 patients positive 
for NOSA (23.8%)
16 patients negative 
for NOSA (76.2%)
16 patients positive
for NOSA (59.3%)
11 patients negative 
for NOSA (40.7%)BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/4
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these former studies positivity for NOSA was associated
with distinct clinical and laboratory variables. Cassani et
al. [7] found an association between NOSA (mostly ANA
and SMA) and female gender, AST and AST values as well
as with necro-inflammatory activity in liver biopsies. The
correlation between ALT and the presence of NOSA could
be reproduced in our series, but there was no association
between the presence of NOSA and either gender or grade
of portal necro-inflammation in liver specimens. The lat-
ter differences are likely due to the different sizes of the
study populations, as other smaller studies could also not
confirm a close relationship between NOSA and gender or
liver histology [16,21]. Interestingly, despite a considera-
ble overlap between groups, the association of ALT values
with positive NOSA seems to be reproducible throughout
different studies [7,22].
The clinically most important finding of our study is the
different efficacy of antiviral therapy with ribavirin and
interferon-α in patients without NOSA as compared to
subjects tested positive for NOSA. Absence of NOSA prior
to and during the combination therapy was associated
with a highly favourable treatment response with an odds
ratio of 4.65 (95% CI 1.31 – 16.48). This association held
true after adjustments for HCV genotypes and HCV-RNA
levels in logistic regression analysis. Since we focused on
immunological parameters in a small cohort of patients, a
positive treatment response was initially defined as any
negative HCV-RNA throughout the course of the study.
However, there was no subject with a viral breakthrough
and only four patients relapsed after completion of the
therapy (two with NOSA, two without NOSA). The re-
analysis with inclusion of the latter patients does support
our major conclusions (OR 6.46, 95% CI 1.54 – 27.19).
These results differ from other studies that could not find
an association between presence of NOSA and efficacy of
antiviral therapy [8,23]. However, the former studies
Table 2: Anti-HCV positive patients with and without serum autoantibodies (ANA, SMA, ANCA, AMA) – comparison of demographic 
variables, clinical, and biochemical parameters.
Autoantibody-negative (n = 42) p**** Autoantibody-positive (n = 36)
Gender (m/f) 16/26 0.81                          15/21
Age (yrs)* 46.1 ± 12.6 0.25                          42.9 ± 12.2
HCV genotype
Genotype 1 and 4 24 0.57                          22
Genotypes 2 and 3/ not detected 18 14
HCV-RNA (copies/ml)* 4.1 × 105 ± 5.5 × 105 0.007 9.1 × 105 ± 9.6 × 105
ALT (U/l)* 27.4 ± 25.0 0.006 47.5 ± 36.3
AST (U/l)* 21.5 ± 26.9 0.11                          33.2 ± 35.9
Albumin (g/l)* 46.0 ± 8.3 0.16                          43.8 ± 4.8
IgG (g/l)* 13.9 ± 3.1 0.08                          15.4 ± 4.0
IgM (g/l)* 2.1 ± 0.9 0.69                          2.2 ± 2.0
IgA (g/l)* 1.4 ± 0.8 0.23                          1.8 ± 1.7
IgG to CMV (pos / neg)*** 22 / 11 0.44                          17 / 14
IgG to EBV (pos / neg)*** 28 / 5 0.99                          28 / 4
Histological score** 1.4 ± 0.8 0.62                          1.5 ± 0.6
Interferon-α treatment [n (%)] 27 (64%) 0.64                          21 (58%)
*Mean ± SD, **Necro-inflammatory activity in liver biopsy were graded from 0 (no activity) to 4 (severe activitiy), ***IgG antibodies to cytomegaly 
virus and Ebstein-Barr virus were determined by ELISA, ****p-values were calculated by Fisher's exact test or Student's t test where appropriate
Table 3: Titers and staining patterns of ANA and SMA in responders and non-responders to antiviral combination therapy.
Responder (n = 21) Non-responder (n = 27) p*
ANA [n (%)] 2 (9.5) 5 (18.5) 0.44
ANA titer [median (range)] 1:80 (1:80 – 1:160) 1:80 (1:40 – 1:320)
Speckled staining pattern [n (%)] 2 (100) 5 (100)
SMA [n (%)] 3 (14.3) 12 (44.4) 0.03
SMA titer [median (range)] 1:40 (1:40–1:80) 1:40 (1:40 – 1:160)
Vessel wall staining pattern [n (%)] 3 (100) 11 (91.7)
*p-values were calculated with Fisher's exact testBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/4
Page 7 of 8
(page number not for citation purposes)
employed interferon monotherapy, whereas combination
therapy (interferon-α plus ribavirin) was used in our
patients only. Furthermore, in two studies [3,7], including
the one with the highest number of patients (n = 144) [7],
a trend towards a poorer response to therapy in patients
with autoantibodies was already noted. In both studies
this trend just failed the 95%-level of statistical
significance.
Why should the addition of ribavirin to antiviral therapy
make a difference? In view of our data and published
results [7,16,19,20,22] the presence of autoantibodies can
be interpreted as a marker for a non-specific activation of
mononuclear cells in response to infection with the hepa-
titis C virus. This might be associated with an attenuation
of the specific immune response and consecutive failure
to clear the virus in a number of patients. This hypothesis
is supported by our finding that patients with NOSA have
a higher viral load compared to subjects without autoan-
tibodies. As ribavirin has distinct immunomodulatory
properties, the addition of this agent to the therapy might
modulate the balance between a specific antiviral and a
non-specific immune response in selected patients. There-
fore, despite the overall benefits of ribavirin, the addition
of this immunomodulatory drug to the therapy could
unmask individual differences in the immune balance
(Th1 versus Th2) with regards to antiviral treatment,
which were not obvious in studies investigating interferon
monotherapy only. In accordance to these findings, a
recent study could demonstrate that the addition of riba-
virin to interferon monotherapy does not modify the thy-
roid autoantibody pattern but increases the risk to
develop hypothyroidism, which was significantly associ-
ated with long-term remission [24]. It is important to note
that safe and efficacious therapy is still lacking for patients
with hepatitis C and (auto)immune abnormalities and
that it is mandatory to be aware of the potentially life-
threatening autoimmune reaction in patients with
chronic hepatitis C and positive NOSA during interferon
therapy. Therefore, further studies with larger numbers of
patients are needed to confirm the clinical relevance of
our findings.
Our observations are related to the immunopathological
discrimination between chronic hepatitis C, autoimmune
hepatitis, and the "hepatitis C-autoimmune-overlap syn-
drome". In our study, we employed the revised scoring
system for the diagnosis of autoimmune hepatitis in order
to exclude a predominant autoimmune liver disease with
sufficient specificity and sensitivity [10,25]. Furthermore,
only one of our patients had low titer SMA without vessel
wall staining pattern and none had ANA with homogene-
ous staining pattern or LKM antibodies, which are closely
correlated to autoimmune hepatitis [26]. Nevertheless,
there are clinical presentations with mixed or atypical fea-
tures because exclusive viral and autoimmune disorders
only represent the two ends of the diagnostic spectrum
[27]. Therefore, in the light of our and previous studies,
NOSA might be determined in order to further stratify
patients with chronic hepatitis C and (auto)immune
abnormalities.
Conclusions
In this study, we were able to demonstrate a negative rela-
tionship between the efficacy of a combined antiviral
treatment with interferon-α plus ribavirin for chronic
hepatitis C and the presence of non-organ-specific
autoantibodies in univariate and multivariate analyses.
However, studies in a larger number of patients should be
performed before generalising our findings with regards
to treatment decisions. Furthermore, future studies
should include the measurement of peripheral immune
parameters, i.e. cytokines and monocyte activation mark-
ers, as well as genetic studies in order to elucidate the
pathophysiological association between the presence of
autoantibodies and a reduced efficacy of combined antivi-
ral treatment with interferon-α and ribavirin.
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